Skip to main content

Advertisement

SpringerLink
Log in

Counseling the Patient with Potentially HPV-Related Newly Diagnosed Head and Neck Cancer

  • Head and Neck Cancers (E Hanna, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

The recent emergence of a clinically distinct subset of head and neck cancers (HNC) caused by infection with the human papillomavirus (HPV) necessitates critical reevaluation of the existing counseling paradigm for patients with newly diagnosed HNC. Herein we propose a structural framework for patient counseling in which HPV testing is incorporated and the impact of HPV-status is discussed in the context of multiple medical and psychosocial domains. We strive to maintain a balance between making recommendations based on the best available scientific evidence and acknowledgment of uncertainty for both patients and providers. We anticipate that both the standard-of-care diagnostic workup and treatment, and counseling guidelines for these patients will change rapidly in the years ahead, as data from ongoing and planned prospective clinical trials become available.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Patel SG, Shah JP. TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin. 2005;55(4):242–58. quiz 261–242, 264.

    PubMed  Google Scholar 

  2. Parkin DM, Ferlay J, Curado MP, et al. Fifty years of cancer incidence: CI5 I-IX. Int J Cancer. 2010;127(12):2918–27.

    CAS  PubMed  Google Scholar 

  3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.

    PubMed  Google Scholar 

  4. Franceschi S, Munoz N, Bosch XF, Snijders PJ, Walboomers JM. Human papillomavirus and cancers of the upper aerodigestive tract: a review of epidemiological and experimental evidence. Cancer Epidemiol Biomarkers Prev. 1996;5(7):567–75.

    CAS  PubMed  Google Scholar 

  5. Mehanna H, Paleri V, West CM, Nutting C. Head and neck cancer–Part 1: Epidemiology, presentation, and prevention. BMJ. 2010;341:c4684.

    CAS  PubMed  Google Scholar 

  6. Rothman K, Keller A. The effect of joint exposure to alcohol and tobacco on risk of cancer of the mouth and pharynx. J Chronic Dis. 1972;25(12):711–6.

    CAS  PubMed  Google Scholar 

  7. Franceschi S, Talamini R, Barra S, et al. Smoking and drinking in relation to cancers of the oral cavity, pharynx, larynx, and esophagus in northern Italy. Cancer Res. 1990;50(20):6502–7.

    CAS  PubMed  Google Scholar 

  8. Mashberg A, Boffetta P, Winkelman R, Garfinkel L. Tobacco smoking, alcohol drinking, and cancer of the oral cavity and oropharynx among U.S. veterans. Cancer. 1993;72(4):1369–75.

    CAS  PubMed  Google Scholar 

  9. Herrero R, Castellsague X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 2003;95(23):1772–83.

    PubMed  Google Scholar 

  10. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26(4):612–9.

    PubMed  Google Scholar 

  11. Kreimer AR, Randi G, Herrero R, Castellsague X, La Vecchia C, Franceschi S. Diet and body mass, and oral and oropharyngeal squamous cell carcinomas: analysis from the IARC multinational case–control study. Int J Cancer. 2006;118(9):2293–7.

    CAS  PubMed  Google Scholar 

  12. Garrote LF, Herrero R, Reyes RM, et al. Risk factors for cancer of the oral cavity and oro-pharynx in Cuba. Br J Cancer. 2001;85(1):46–54.

    CAS  PubMed Central  PubMed  Google Scholar 

  13. Talamini R, Vaccarella S, Barbone F, et al. Oral hygiene, dentition, sexual habits and risk of oral cancer. Br J Cancer. 2000;83(9):1238–42.

    CAS  PubMed Central  PubMed  Google Scholar 

  14. Bundgaard T, Wildt J, Frydenberg M, Elbrond O, Nielsen JE. Case–control study of squamous cell cancer of the oral cavity in Denmark. Cancer Causes Control. 1995;6(1):57–67.

    CAS  PubMed  Google Scholar 

  15. Suarez C, Rodrigo JP, Ferlito A, Cabanillas R, Shaha AR, Rinaldo A. Tumours of familial origin in the head and neck. Oral Oncol. 2006;42(10):965–78.

    PubMed  Google Scholar 

  16. Foulkes WD, Brunet JS, Sieh W, Black MJ, Shenouda G, Narod SA. Familial risks of squamous cell carcinoma of the head and neck: retrospective case–control study. BMJ. 1996;313(7059):716–21.

    CAS  PubMed  Google Scholar 

  17. Trizna Z, Schantz SP. Hereditary and environmental factors associated with risk and progression of head and neck cancer. Otolaryngol Clin North Am. 1992;25(5):1089–103.

    CAS  PubMed  Google Scholar 

  18. Schantz SP, Yu GP. Head and neck cancer incidence trends in young Americans, 1973–1997, with a special analysis for tongue cancer. Arch Otolaryngol Head Neck Surg. 2002;128(3):268–74.

    PubMed  Google Scholar 

  19. Devesa SS, Blot WJ, Fraumeni Jr JF. Cohort trends in mortality from oral, esophageal, and laryngeal cancers in the United States. Epidemiology. 1990;1(2):116–21.

    CAS  PubMed  Google Scholar 

  20. Canto MT, Devesa SS. Oral cavity and pharynx cancer incidence rates in the United States, 1975–1998. Oral Oncol. 2002;38(6):610–7.

    PubMed  Google Scholar 

  21. Shiboski CH, Shiboski SC, Silverman Jr S. Trends in oral cancer rates in the United States, 1973–1996. Community Dent Oral Epidemiol. 2000;28(4):249–56.

    CAS  PubMed  Google Scholar 

  22. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294–301.

    PubMed  Google Scholar 

  23. Hammarstedt L, Lindquist D, Dahlstrand H, et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer. 2006;119(11):2620–3.

    CAS  PubMed  Google Scholar 

  24. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20–44 years. Cancer. 2005;103(9):1843–9.

    PubMed  Google Scholar 

  25. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92(9):709–20.

    CAS  PubMed  Google Scholar 

  26. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.

    CAS  PubMed Central  PubMed  Google Scholar 

  27. D'Souza G, Kreimer AR, Viscidi R, et al. Case–control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356(19):1944–56.

    PubMed  Google Scholar 

  28. Sikora AG, Morris LG, Sturgis EM. Bidirectional association of anogenital and oral cavity/pharyngeal carcinomas in men. Arch Otolaryngol Head Neck Surg. 2009;135(4):402–5.

    PubMed  Google Scholar 

  29. Nguyen NP, Ly BH, Betz M, Vinh-Hung V. Importance of age as a prognostic factor for tonsillar carcinoma. Ann Surg Oncol. 2010;17(10):2570–7.

    PubMed  Google Scholar 

  30. Kreimer AR, Alberg AJ, Daniel R, et al. Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis. 2004;189(4):686–98.

    PubMed  Google Scholar 

  31. Heck JE, Berthiller J, Vaccarella S, et al. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol. 2010;39(1):166–81.

    PubMed  Google Scholar 

  32. Schwartz SM, Daling JR, Doody DR, et al. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst. 1998;90(21):1626–36.

    CAS  PubMed  Google Scholar 

  33. Hansson BG, Rosenquist K, Antonsson A, et al. Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: a population-based case–control study in southern Sweden. Acta Otolaryngol. 2005;125(12):1337–44.

    PubMed  Google Scholar 

  34. Smith EM, Ritchie JM, Summersgill KF, et al. Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst. 2004;96(6):449–55.

    PubMed  Google Scholar 

  35. Reimers N, Kasper HU, Weissenborn SJ, et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer. 2007;120(8):1731–8.

    CAS  PubMed  Google Scholar 

  36. Hafkamp HC, Speel EJ, Haesevoets A, et al. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5–8. Int J Cancer. 2003;107(3):394–400.

    CAS  PubMed  Google Scholar 

  37. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467–75.

    CAS  PubMed  Google Scholar 

  38. Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med. 2001;344(15):1125–31.

    CAS  PubMed  Google Scholar 

  39. O'Rorke MA, Ellison MV, Murray LJ, Moran M, James J, Anderson LA. Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. Oral Oncol. 2012;48(12):1191–201.

    PubMed  Google Scholar 

  40. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157(3):218–26.

    PubMed  Google Scholar 

  41. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol. 2004;31(6):744–54.

    PubMed  Google Scholar 

  42. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009–2010. JAMA. 2012;307(7):693–703.

    CAS  PubMed  Google Scholar 

  43. Rintala M, Grenman S, Puranen M, Syrjanen S. Natural history of oral papillomavirus infections in spouses: a prospective Finnish HPV Family Study. J Clin Virol. 2006;35(1):89–94.

    PubMed  Google Scholar 

  44. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008;359(11):1143–54.

    CAS  PubMed  Google Scholar 

  45. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res. 2002;89(2):213–28.

    CAS  PubMed  Google Scholar 

  46. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–27.

    PubMed  Google Scholar 

  47. McDougall JK. Immortalization and transformation of human cells by human papillomavirus. Curr Top Microbiol Immunol. 1994;186:101–19.

    CAS  PubMed  Google Scholar 

  48. Gillison ML, Lowy DR. A causal role for human papillomavirus in head and neck cancer. Lancet. 2004;363(9420):1488–9.

    CAS  PubMed  Google Scholar 

  49. Lohavanichbutr P, Houck J, Fan W, et al. Genomewide gene expression profiles of HPV-positive and HPV-negative oropharyngeal cancer: potential implications for treatment choices. Arch Otolaryngol Head Neck Surg. 2009;135(2):180–8.

    PubMed Central  PubMed  Google Scholar 

  50. Klussmann JP, Mooren JJ, Lehnen M, et al. Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications. Clin Cancer Res. 2009;15(5):1779–86.

    CAS  PubMed  Google Scholar 

  51. Braakhuis BJ, Snijders PJ, Keune WJ, et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst. 2004;96(13):998–1006.

    CAS  PubMed  Google Scholar 

  52. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333(6046):1157–60.

    CAS  PubMed Central  PubMed  Google Scholar 

  53. Agrawal N, Frederick MJ, Pickering CR, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333(6046):1154–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  54. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357(25):2552–61.

    CAS  PubMed Central  PubMed  Google Scholar 

  55. Westra WH, Taube JM, Poeta ML, Begum S, Sidransky D, Koch WM. Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2008;14(2):366–9.

    CAS  PubMed  Google Scholar 

  56. Schwarz E, Freese UK, Gissmann L, et al. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 1985;314(6006):111–4.

    CAS  PubMed  Google Scholar 

  57. Crook T, Morgenstern JP, Crawford L, Banks L. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J. 1989;8(2):513–9.

    CAS  PubMed  Google Scholar 

  58. Howley PM. Role of the human papillomaviruses in human cancer. Cancer Res. 1991;51(18 Suppl):5019s–22s.

    CAS  PubMed  Google Scholar 

  59. Nasseri M, Gage JR, Lorincz A, Wettstein FO. Human papillomavirus type 16 immortalized cervical keratinocytes contain transcripts encoding E6, E7, and E2 initiated at the P97 promoter and express high levels of E7. Virology. 1991;184(1):131–40.

    CAS  PubMed  Google Scholar 

  60. Rampias T, Sasaki C, Weinberger P, Psyrri A. E6 and e7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst. 2009;101(6):412–23.

    CAS  PubMed  Google Scholar 

  61. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990;248(4951):76–9.

    CAS  PubMed  Google Scholar 

  62. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 1993;75(3):495–505.

    CAS  PubMed  Google Scholar 

  63. Munger K, Werness BA, Dyson N, Phelps WC, Harlow E, Howley PM. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 1989;8(13):4099–105.

    CAS  PubMed  Google Scholar 

  64. Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene. 2002;21(10):1510–7.

    CAS  PubMed  Google Scholar 

  65. Wilczynski SP, Lin BT, Xie Y, Paz IB. Detection of human papillomavirus DNA and oncoprotein overexpression are associated with distinct morphological patterns of tonsillar squamous cell carcinoma. Am J Pathol. 1998;152(1):145–56.

    CAS  PubMed  Google Scholar 

  66. Galloway DA, McDougall JK. The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia. Semin Cancer Biol. 1996;7(6):309–15.

    CAS  PubMed  Google Scholar 

  67. Veldman T, Horikawa I, Barrett JC, Schlegel R. Transcriptional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J Virol. 2001;75(9):4467–72.

    CAS  PubMed Central  PubMed  Google Scholar 

  68. Chu A, Genden E, Posner M, Sikora A. A patient-centered approach to counseling patients with head and neck cancer undergoing human papillomavirus testing: a clinician's guide. Oncologist. 2013;18(2):180–9.

    PubMed  Google Scholar 

  69. De Boer MF, McCormick LK, Pruyn JF, Ryckman RM, van den Borne BW. Physical and psychosocial correlates of head and neck cancer: a review of the literature. Otolaryngol Head Neck Surg. 1999;120(3):427–36.

    PubMed  Google Scholar 

  70. Kugaya A, Akechi T, Okuyama T, et al. Prevalence, predictive factors, and screening for psychologic distress in patients with newly diagnosed head and neck cancer. Cancer. 2000;88(12):2817–23.

    CAS  PubMed  Google Scholar 

  71. Verdonck-de Leeuw IM, de Bree R, Keizer AL, et al. Computerized prospective screening for high levels of emotional distress in head and neck cancer patients and referral rate to psychosocial care. Oral Oncol. 2009;45(10):e129–133.

    PubMed  Google Scholar 

  72. Kwan TT, Cheung AN, Lo SS, et al. Psychological burden of testing positive for high-risk human papillomavirus on women with atypical cervical cytology: a prospective study. Acta Obstet Gynecol Scand. 2011;90(5):445–51.

    PubMed  Google Scholar 

  73. Daley EM, Perrin KM, McDermott RJ, et al. The psychosocial burden of HPV: a mixed-method study of knowledge, attitudes and behaviors among HPV + women. J Health Psychol. 2010;15(2):279–90.

    PubMed  Google Scholar 

  74. Fortenberry JD. The effects of stigma on genital herpes care-seeking behaviours. Herpes. 2004;11(1):8–11.

    PubMed  Google Scholar 

  75. Milbury K, Rosenthal DI, El-Naggar A, Badr H. An exploratory study of the informational and psychosocial needs of patients with human papillomavirus-associated oropharyngeal cancer. Oral Oncol. 2013;49(11):1067–71.

    PubMed  Google Scholar 

  76. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(Rr-2):1–24.

    PubMed  Google Scholar 

  77. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59(20):626–629.

  78. Recommendations on the use of quadrivalent human papillomavirus vaccine in males–Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60(50):1705–1708.

    Google Scholar 

  79. Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer. 2007;121(8):1813–20.

    CAS  PubMed  Google Scholar 

  80. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010;2:15.

    PubMed Central  PubMed  Google Scholar 

  81. Weinberger PM, Yu Z, Haffty BG, et al. Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clin Cancer Res. 2004;10(17):5684–91.

    CAS  PubMed  Google Scholar 

  82. Paz IB, Cook N, Odom-Maryon T, Xie Y, Wilczynski SP. Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. Cancer. 1997;79(3):595–604.

    CAS  PubMed  Google Scholar 

  83. Vila P. Decreased Impact Of Nodal Positivity On Oropharyngeal Cancer Survival In The HPV Era: A Population Based Study. In: Genden E, Morris L, Posner M, Boffetta P, Sikora A, eds. European Archives of Oto-Rhino-Laryngology and Head and Neck; (In press).

  84. Jain KS, Sikora AG, Baxi SS, Morris LG. Synchronous cancers in patients with head and neck cancer: risks in the era of human papillomavirus-associated oropharyngeal cancer. Cancer. 2013;119(10):1832–7.

    PubMed  Google Scholar 

  85. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol. 2006;24(17):2606–11.

    PubMed  Google Scholar 

  86. Weinberger PM, Yu Z, Haffty BG, et al. Molecular classification identifies a subset of human papillomavirus–associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006;24(5):736–47.

    CAS  PubMed  Google Scholar 

  87. Schlecht NF. Prognostic value of human papillomavirus in the survival of head and neck cancer patients: an overview of the evidence. Oncol Rep. 2005;14(5):1239–47.

    CAS  PubMed  Google Scholar 

  88. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer. 2001;92(4):805–13.

    CAS  PubMed  Google Scholar 

  89. Morris LG, Sikora AG, Patel SG, Hayes RB, Ganly I. Second primary cancers after an index head and neck cancer: subsite-specific trends in the era of human papillomavirus-associated oropharyngeal cancer. J Clin Oncol. 2011;29(6):739–46.

    PubMed  Google Scholar 

  90. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol. 2006;24(36):5630–6.

    CAS  PubMed  Google Scholar 

  91. de Jong MC, Pramana J, Knegjens JL, et al. HPV and high-risk gene expression profiles predict response to chemoradiotherapy in head and neck cancer, independent of clinical factors. Radiother Oncol. 2010;95(3):365–70.

    PubMed  Google Scholar 

  92. Posner MR, Lorch JH, Goloubeva O, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol. 2011;22(5):1071–7.

    CAS  PubMed  Google Scholar 

  93. Lacy PD, Piccirillo JF, Merritt MG, Zequeira MR. Head and neck squamous cell carcinoma: better to be young. Otolaryngol Head Neck Surg. 2000;122(2):253–8.

    CAS  PubMed  Google Scholar 

  94. Vu HL, Sikora AG, Fu S, Kao J. HPV-induced oropharyngeal cancer, immune response and response to therapy. Cancer Lett. 2010;288(2):149–55.

    CAS  PubMed  Google Scholar 

  95. Hafkamp HC, Manni JJ, Haesevoets A, et al. Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer. 2008;122(12):2656–64.

    CAS  PubMed  Google Scholar 

  96. Mayne ST, Cartmel B, Kirsh V, Goodwin Jr WJ. Alcohol and tobacco use prediagnosis and postdiagnosis, and survival in a cohort of patients with early stage cancers of the oral cavity, pharynx, and larynx. Cancer Epidemiol Biomarkers Prev. 2009;18(12):3368–74.

    CAS  PubMed Central  PubMed  Google Scholar 

  97. Gillison ML, Zhang Q, Jordan R, et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol. 2012;30(17):2102–11.

    CAS  PubMed  Google Scholar 

  98. West R. Assessment of dependence and motivation to stop smoking. BMJ. 2004;328(7435):338–9.

    PubMed  Google Scholar 

  99. Lancaster T, Stead L. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2004;4, Cd000165.

    PubMed  Google Scholar 

  100. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med. 2008;35(2):158–176.

    Google Scholar 

  101. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142(4):233–9.

    PubMed  Google Scholar 

  102. Cummings KM, Mahoney M. Current and emerging treatment approaches for tobacco dependence. Curr Oncol Rep. 2006;8(6):475–83.

    PubMed  Google Scholar 

  103. Stead LF, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst Rev. 2012;10, Cd008286.

    PubMed  Google Scholar 

  104. Vakharia KT, Ali MJ, Wang SJ. Quality-of-life impact of participation in a head and neck cancer support group. Otolaryngol Head Neck Surg. 2007;136(3):405–10.

    PubMed  Google Scholar 

  105. Mowry SE, Wang MB. The influence of support groups on quality of life in head and neck cancer patients. ISRN Otolaryngol. 2011;2011:250142.

    PubMed Central  PubMed  Google Scholar 

  106. Singhi AD, Westra WH. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer. 2010;116(9):2166–73.

    PubMed  Google Scholar 

  107. Clavel C, Masure M, Bory JP, et al. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer. 1999;80(9):1306–11.

    CAS  PubMed Central  PubMed  Google Scholar 

  108. Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer. 2001;84(12):1616–23.

    CAS  PubMed Central  PubMed  Google Scholar 

  109. Lindquist D, Romanitan M, Hammarstedt L, et al. Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7. Mol Oncol. 2007;1(3):350–5.

    PubMed  Google Scholar 

  110. Shi W, Kato H, Perez-Ordonez B, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol. 2009;27(36):6213–21.

    PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

ᅟ

Conflict of Interest

John P. Finnigan and Andrew G. Sikora declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, USA

    John P. Finnigan Jr & Andrew G. Sikora

  2. Department of Oncologic Sciences, Icahn School of Medicine at Mount Sinai, New York, USA

    Andrew G. Sikora

  3. Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, USA

    Andrew G. Sikora

  4. Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, USA

    Andrew G. Sikora

  5. Tish Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA

    Andrew G. Sikora

  6. One Gustave L. Levy Place, Box 1189, New York, NY, 10029, USA

    Andrew G. Sikora

Authors
  1. John P. Finnigan Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew G. Sikora
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew G. Sikora.

Additional information

This article is part of the Topical Collection on Head and Neck Cancers

Rights and permissions

Reprints and permissions

About this article

Cite this article

Finnigan, J.P., Sikora, A.G. Counseling the Patient with Potentially HPV-Related Newly Diagnosed Head and Neck Cancer. Curr Oncol Rep 16, 375 (2014). https://doi.org/10.1007/s11912-013-0375-8

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-013-0375-8

Keywords

Search

Navigation